Lv1
20 积分 2024-11-10 加入
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
2小时前
已完结
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials
2小时前
待确认
A meta-analysis of randomized controlled clinical trials implications of acute treatment effects on glomerular filtration rate for long-term kidney protection
5天前
已完结
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure
8天前
已完结
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
8天前
已完结
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
9天前
已完结
Ertugliflozin and Slope of Chronic eGFR
9天前
已完结
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
9天前
已完结
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
9天前
已完结
The effect of dapagliflozin on renal function in patients with type 2 diabetes
10天前
已完结
皖公网安备34019202002308
